India and Uzbekistan Launch Pharma–Nutraceutical Corridor to Access $10 Billion Eurasian Market

India and Uzbekistan have jointly launched a pharmaceutical and nutraceutical trade corridor aimed at expanding market access for healthcare products across the Commonwealth of Independent States (CIS) and the wider Eurasian region. The initiative seeks to create a structured platform for regulatory cooperation, investment facilitation, and cross-border trade, enabling Indian manufacturers to reach a rapidly growing healthcare market estimated at $7–10 billion.

Uzbekistan Emerging as Eurasian Pharma Gateway

Uzbekistan is positioning itself as a strategic hub for pharmaceutical and nutraceutical trade by developing pharma parks, modernizing regulatory frameworks, and attracting foreign investment. Its geographic location between India, Russia, and Central Asia allows it to function as a gateway for companies seeking access to CIS markets and broader Eurasian healthcare supply chains.

Industry Platform to Drive Partnerships and Market Entry

The corridor will be operationalized through industry collaboration platforms such as Pharma Eurasia 2026 in Tashkent, where pharmaceutical companies, regulators, and investors will explore partnerships and distribution networks. The initiative is expected to streamline regulatory approvals, support joint ventures, and strengthen supply chain integration for Indian pharmaceutical and nutraceutical exporters.